Chromosomal translocations that involve the MOZ gene 3 (official gene symbol Myst3) are typically associated with acute myelomonocytic leukemia and predict a poor prognosis 4 . Whereas MOZ is essential for the self-renewal of hematopoietic stem cells 5, 6 , MOZ fusion proteins enable the transformation of non-self-renewing myeloid progenitors into leukemia stem cells 7 . We previously generated a mouse model for AML by introducing c-Kit + mouse myeloid stem/progenitor cells infected with a retrovirus encoding MOZ-TIF2 and EGFP into lethally irradiated mice 8 .
Chromosomal translocations that involve the MOZ gene 3 (official gene symbol Myst3) are typically associated with acute myelomonocytic leukemia and predict a poor prognosis 4 . Whereas MOZ is essential for the self-renewal of hematopoietic stem cells 5, 6 , MOZ fusion proteins enable the transformation of non-self-renewing myeloid progenitors into leukemia stem cells 7 . We previously generated a mouse model for AML by introducing c-Kit + mouse myeloid stem/progenitor cells infected with a retrovirus encoding MOZ-TIF2 and EGFP into lethally irradiated mice 8 .
To identify leukemia-initiating cells (LICs), we investigated the bone marrow cells of these mice for various cell surface markers by FACS analysis. CSF1R high and CSF1R low cells were present in the bone marrow ( Fig. 1a) and expressed equivalent amounts of MOZ-TIF2 protein (Fig. 1b) . To determine the LIC activity of these cell populations, we isolated CSF1R high and CSF1R low cells by cell sorting and transplanted limited numbers (10 to 1 × 10 4 cells) into irradiated mice. One hundred CSF1R high cells were sufficient to induce AML in all transplanted mice (Fig. 1c) . Conversely, no mice developed AML after 1 × 10 3 CSF1R low cells were transplanted per mouse, and only half of the mice developed AML with delayed onset when 1 × 10 4 CSF1R low cells were transplanted (Fig. 1d) . Thus, the CSF1R high cells showed a >100-fold stronger LIC activity than CSF1R low cells.
FACS analysis indicated that the CSF1R high cell population had the phenotype of both granulocyte-macrophage progenitors (GMPs, Kit + Sca-1 − CD16/CD32 + ) and differentiated monocytes (Mac-1 low Gr-1 + ) (Supplementary Fig. 1a) . Comparison of the CSF1R high and CSF1R low cell populations indicated that Mac-1 expression was lower in CSF1R high than in CSF1R low cells (Fig. 1e) . However, we did not observe significant differences between the CSF1R high and CSF1R low cell populations with respect to their cell morphology (Fig. 1f) , colony-forming ability in methylcellulose medium (Fig. 1g) , cell cycle distribution ( Supplementary  Fig. 1b ) or homeobox A9 (HoxA9) expression (Supplementary Fig. 1c ). To investigate whether downstream pathways of CSF1R signaling were activated, we measured phosphorylation levels of signal transducer and activator of traranscription-5 (STAT5) and extracellular signal-regulated kinase (ERK) in CSF1R high and CSF1R low cells. STAT5 was highly phosphorylated in the CSF1R high cell population but not in the CSF1R low population, whereas ERK was equivalently phosphorylated in the two cell populations (Fig. 1h) .
Side population cells, which are present in some types of normal and malignant stem cell populations, were present in the bone marrow of MOZ-TIF2-induced AML mice (Supplementary Fig. 2a) . Whereas most side population cells were CSF1R high , the non-side population fraction contained both CSFR1 high and CSF1R low cells (Supplementary Fig. 2b ). LICs were approximately tenfold more enriched in the side population fraction than in the non-side population fraction (Supplementary Fig. 2c,d ). Because the side population fraction was very small (~0.12% of total bone marrow cells), the fraction of LICs in the side population fraction was also small (~1% of all LICs), and most LICs were present in the non-side population fraction (~99%). To determine whether a high level of CSF1R expression also occurs in human AML cells with MOZ translocations, we investigated CSF1R expression in bone marrow cells from a subject with AML harboring a t(8;16) translocation, yielding a MOZ-CREB-binding protein (CBP, encoded by the Crebbp gene) fusion 9 . FACS analysis indicated that both CSF1R high and CSF1R low cells were present among the bone marrow cells with this translocation (Fig. 1i) . We detected MOZ-CBP fusion transcripts in both the CSF1R high and CSF1R low cell populations (Fig. 1j) .
These results suggest that leukemia stem cells in this subtype of AML express a high amount of CSF1R, indicating that leukemia might be cured by inducing apoptosis of CSF1R high cells. To test this idea, we used transgenic mice expressing a drug-inducible FK506-binding protein (FKBP)-Fas suicide gene and EGFP under the control of the CSF1R promoter 10 (Fig. 2a) . The suicide gene products are inactive monomers under normal conditions but can be activated by injection of the AP20187 dimerizer, inducing apoptosis of cells expressing high amounts of CSF1R 10 . We infected c-Kit + bone marrow cells of transgenic mice with the MOZ-TIF2 retrovirus and transplanted them into lethally irradiated wild-type mice. These mice developed AML ~2 months after transplantation. In the bone marrow of these mice, we observed morphologically indistinguishable CSF1R high and CSF1R low cells. As expected, endogenous CSF1R expression was proportional to EGFP and FKBP-Fas expression ( Fig. 2b and Supplementary Fig. 3a) .
Next, we transplanted the bone marrow cells of these AML mice (1 × 10 5 cells per mouse) into secondary sublethally irradiated recipient mice. Seven days after transplantation, we injected the mice with AP20187 or a control solvent, as previously described 10 . We observed an increase in the number of CSF1R high cells (Fig. 2c) and splenomegaly ( Fig. 2d) in the control-treated mice 3 weeks after transplantation. However, we detected neither CSF1R high cells nor splenomegaly in the AP20187-treated mice after a 1-week course of treatment (Fig. 2c,d ). Although we observed CSF1R low cells in the bone marrow and peripheral blood after the 1-week treatment course, we did not detect these cells after three months of treatment ( Fig. 2c and Supplementary Fig. 3b ). All control-treated mice developed AML 4-6 weeks after transplantation, but none of the AP20187-treated mice died of AML within 6 months of transplantation (Fig. 2e) . These results indicate that ablation of the CSF1R high cells was sufficient to cure MOZ-TIF2-induced AML, and that a high level of CSF1R expression is a key contributor to leukemia stem cell potential.
As it has been reported that N-Myc overexpression rapidly causes AML in mice 11 , we next tested the specificity of the requirement for CSF1R high cells in AML progression. We transfected the bone marrow cells of suicide gene-expressing transgenic mice with a retrovirus encoding N-Myc and EGFP, and transplanted the cells into lethally irradiated recipient mice, which developed AML. In these mice, GFP + leukemia cells were Mac1 + Gr1 + CSF1R − blast cells ( Supplementary  Fig. 4a,b) , and treatment with AP20187 did not affect AML induction (Supplementary Fig. 4c) . These results indicate a specific role of CSFR expression in MOZ-TIF2-induced AML.
To investigate the role of CSF1R in the development of MOZ-TIF2-induced AML, we infected wild-type and Csf1r −/− (ref. 12) mouse fetal liver cells of embryonic day 16.5 (E16.5) littermate embryos with the MOZ-TIF2 virus and transplanted them into lethally irradiated mice. All mice transplanted with wild-type cells developed AML within 3 months (Fig. 3a) . In contrast, AML induction was initially suppressed in mice transplanted with Csf1r −/− cells, but half of the mice developed AML after a longer latency period (Fig. 3a) . The suppression of AML was rescued by co-infection with the retrovirus encoding CSF1R (Fig. 3b) . STAT5, which was highly phosphorylated in CSF1R high cells but not in CSF1R low cells (Fig. 1h) , was phosphorylated in the bone marrow of recipient mice transplanted with Csf1r +/+ cells but not with Csf1r −/− cells (Supplementary Fig. 5 ). To test the specificity of the requirement of CSF1R for AML induction by MOZ-TIF2, we transfected Csf1r +/+ and Csf1r −/− fetal liver cells with the retrovirus encoding N-Myc and transplanted them into irradiated recipient mice. All of the mice transplanted with either Csf1r +/+ or Csf1r −/− cells expressing N-Myc developed AML ( Supplementary  Fig. 4d ). These results indicate that CSF1R has a key role in AML induction by MOZ-TIF2, but not by N-Myc.
The above results suggest that signaling through CSF1R might be a therapeutic target for kinase inhibitors in leukemogenesis induced by MOZ fusions. To test this, we used the CSF1R-specific inhibitor Ki20227 (ref. 13 ) and the tyrosine kinase inhibitor imatinib mesylate (STI571), which inhibits CSF1R1 [14] [15] [16] . Oral administration of Ki20227 or imatinib inhibited MOZ-TIF2-induced splenomegaly (Fig. 3c) and slowed MOZ-TIF2-induced AML onset (Fig. 3d) . However, the drugs did not affect the progress of N-Myc-induced AML (Fig. 3e) .
Next, we investigated the molecular mechanism of CSF1R expression in the leukemia cells. Monocyte-specific expression of CSF1R is reportedly regulated by transcription factors such as AML1, PU.1 and CCAAT/enhancer-binding proteins (C/EBPs) 17 . We previously found that MOZ interacts with AML1 and PU.1, but not with C/EBPα or C/EBPε, to stimulate transcription of their target genes 5, 18 . Deletion analysis indicated that PU.1 interacted with the N-terminal and central regions of MOZ ( Fig. 4a and Supplementary Fig. 6 ), and that the acidic amino acid-rich region (DE region) of PU.1 was required for its high-affinity interaction with MOZ ( Fig. 4a and Supplementary  Fig. 7a-d) . Although binding of PU.1 to N-terminal MOZ (amino acids 1-513) was inhibited by several deletions in the PU.1 protein (Supplementary Fig. 7c ), binding to full-length MOZ was not completely inhibited by these deletions (Supplementary Fig. 7b ), suggesting that there may be other PU.1-binding sites in MOZ, its associated proteins or both. A pull-down assay with Escherichia coliproduced GST-PU.1 or GST-AML1 and in vitro-produced N-terminal MOZ indicated a direct interaction between both PU.1 and MOZ and between AML1 and MOZ (Supplementary Fig. 8 ). However, we cannot rule out a possibility that other factors may facilitate interactions between PU.1 or AML1 and MOZ in vivo.
To investigate transcriptional regulation of CSF1R, we performed reporter analysis with a CSF1R promoter-luciferase construct and found that MOZ, MOZ-TIF2 and MOZ-CBP could all activate the CSF1R promoter in the presence of PU.1 but not in the presence of AML1 (Fig. 4b) . Moreover, MOZ, MOZ-TIF2 and MOZ-CBP did not activate a CSF1R promoter mutant lacking PU.1-binding sites (Fig. 4c) . These results suggest that MOZ and MOZ fusion proteins activate CSF1R transcription in a PU. Figs. 7e and 9) . A truncated version of MOZ (1-1518) lacking the C-terminal region failed to activate transcription, indicating that the transcriptional activity of MOZ-TIF2 and MOZ-CBP, which do not contain that C-terminal region, requires the TIF2 or CBP portion of the fusion protein.
To test the requirement of PU.1 for the expression of endogenous CSF1R, we used PU.1-deficient (Sfpi1 −/− ) myeloid progenitors expressing the PU.1-estrogen receptor fusion protein (PUER). Upon restoration of PU.1 activity by exposure to 4-hydroxytamoxifen (4-HT), PUER cells can differentiate into macrophages 20 . We infected PUER cells with the MOZ-TIF2 retrovirus or control retrovirus, sorted them for GFP expression and cultured the GFP + cells in the presence of 4-HT. The results of FACS (Fig. 4d) and quantitative RT-PCR (Supplementary Fig. 10 ) analyses indicated that CSF1R expression was induced after exposure to 4-HT, and that MOZ-TIF2 enhanced (Fig. 4d) . We did not detect CSF1R expression before addition of 4-HT, even in PUER cells expressing MOZ-TIF2 (Fig. 4d) , indicating that functional PU.1 is required for MOZ-TIF2-induced CSF1R expression. Chromatin immunoprecipitation (ChIP) analysis indicated that PU.1, MOZ-TIF2 and possibly endogenous MOZ were recruited to the Csf1r promoter in the bone marrow cells of mice with MOZ-TIF2-induced AML ( Supplementary  Fig. 11a) . In PUER cells expressing MOZ-TIF2, recruitment of MOZ-TIF2 and MOZ to the Csf1r promoter was detected after 4-HT treatment, but not before the treatment (Supplementary Fig. 11b) , suggesting that the recruitment of MOZ-TIF2 and MOZ is dependent upon functional PU.1.
To determine whether PU.1 is essential for the development of MOZ-TIF2-induced AML, we infected wild-type and Sfpi1 −/− fetal liver cells of E12.5 littermates with retroviruses encoding MOZ-TIF2 or N-Myc and transplanted them into irradiated mice. Although mice transplanted with Sfpi1 +/+ cells expressing MOZ-TIF2 developed AML 8-14 weeks after transplantation, mice transplanted with Sfpi1 −/− cells were healthy for at least 6 months (Fig. 4e) . In contrast, all mice transplanted with either wild-type or Sfpi1 −/− cells expressing N-Myc developed AML 6-10 weeks after transplantation (Fig. 4f) . When both PU.1 and MOZ-TIF2 were introduced into PU.1-deficient fetal liver cells, the transplanted mice developed leukemia (Fig. 4g) . However, introduction of either PU.1 or MOZ-TIF2 alone was not sufficient for AML induction. Thus, we conclude that PU.1 is required for the initiation of MOZ-TIF2-induced AML.
To determine whether PU.1 is also required for the maintenance of MOZ-TIF2-induced AML, we infected fetal liver cells of PU.1 conditional knockout mice (Sfpi1 flox/flox and expressing estrogen receptor (ER)-Cre) with MOZ-TIF2 and transplanted them into irradiated recipient mice, which developed AML. We next transplanted bone marrow cells of these mice into irradiated secondary recipients and then treated half of the mice with tamoxifen to induce PU.1 deletion. All of the control mice died of AML within 6 weeks, but none of the tamoxifentreated mice developed AML for at least for 6 months (Fig. 4h) . These results indicate that PU.1 is also required for the maintenance of MOZ-TIF2-induced AML stem cells.
Taken together, our results indicate that MOZ and its leukemiaassociated fusion proteins activate PU.1-mediated transcription of the monocyte-specific gene Csf1r. MOZ fusion proteins might constitutively stimulate high Csf1r expression to induce AML (Fig. 4i) . In contrast, we previously found that MOZ fusion proteins inhibit AML1-mediated activation of granulocyte-specific Mpo gene transcription 18 . Because MOZ fusion proteins are associated with monocytic leukemia, commitment to the monocytic lineage may be determined by differential regulation of target genes by MOZ fusion proteins (that is, upregulation of monocyte-specific genes such as Csf1r and downregulation of granulocyte-specific genes such as that encoding myeloperoxidase). It is also likely that the normal MOZ protein modulates Csf1r expression to an appropriate level to regulate normal hematopoiesis (Fig. 4i) , as Csf1r expression was impaired in MOZ −/− fetal liver cells (Supplementary Fig. 12 ).
Although AML induction was suppressed in mice transplanted with Csf1r −/− cells, half of these mice developed AML, albeit at a longer latency. Thus, MOZ-TIF2 can provoke either a rapid induction of AML in a CSF1R-dependent manner or a slower induction in a CSF1R-independent manner. There are several possibilities to explain this CSF1R independence. First, we observed increased HoxA9 expression in both CSF1R high and CSF1R low cells. HoxA9 overexpression is reportedly not sufficient to induce AML and additional mutations or oncogene activation is required for AML induction in this context 21, 22 . Thus, MOZ-TIF2-transfected Csf1r −/− cells might require additional mutations to induce leukemia. Second, because we used a retrovirus vector to introduce MOZ-TIF2, it is possible that oncogene activation by retroviral integration might mediate AML pathogenesis.
In conclusion, our results indicate that PU.1-mediated upregulation of Csf1r is crucial for leukemia stem cell potential induced by MOZ-TIF2. Our findings add to previous work associating CSF1R with AML. CSF1R upregulation has been reported in human [23] [24] [25] and mouse 26 AML. CSF1R is also known as the oncoprotein c-Fms, and transplantation of bone marrow cells expressing the v-fms oncoprotein induces multilineage hematopoietic disorders 27 . A chromosomal translocation resulting in expression of a fusion protein in which RNA-binding motif protein-6 (RBM6) is fused to CSF1R has recently been reported to be associated with AML 28 . CSF1R may thus be crucial for not only leukemia induced by MOZ fusions but also a wider subset of AML.
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